WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 529318

CAS#: 581-05-5

Description: CZEN-002 is a NF-κB activation inhibitor potentially for the treatment of vulvovaginal candidiasis

Chemical Structure

CAS# 581-05-5

Theoretical Analysis

MedKoo Cat#: 529318
Name: CZEN-002
CAS#: 581-05-5
Chemical Formula: C77H109N21O19S
Exact Mass: 1663.7929
Molecular Weight: 1664.9
Elemental Analysis: C, 55.55; H, 6.60; N, 17.67; O, 18.26; S, 1.93

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: CZEN-002; CZEN002; CZEN 002; Melanotropin; a-​Melanotropin; ALPHA-​MSH; a-MSH; a-​Melanocyte Stimulating Hormone;

IUPAC/Chemical Name: (4S,7S,10S,13S,16S,22S)-7-((1H-imidazol-4-yl)methyl)-16-((1H-indol-3-yl)methyl)-26-amino-22-((S)-2-(((S)-1-amino-3-methyl-1-oxobutan-2-yl)carbamoyl)pyrrolidine-1-carbonyl)-10-benzyl-13-(3-guanidinopropyl)-4-((2S,5S,8S,11S)-8-(4-hydroxybenzyl)-5,11-bis(hydroxymethyl)-2-(2-(methylthio)ethyl)-4,7,10,13-tetraoxo-3,6,9,12-tetraazatetradecanamido)-5,8,11,14,17,20-hexaoxo-6,9,12,15,18,21-hexaazahexacosanoic acid


InChi Code: InChI=1S/C77H109N21O19S/c1-42(2)64(65(79)106)97-75(116)61-20-13-30-98(61)76(117)54(18-10-11-28-78)88-62(103)38-85-66(107)57(34-46-36-84-50-17-9-8-16-49(46)50)94-67(108)51(19-12-29-83-77(80)81)89-70(111)55(32-44-14-6-5-7-15-44)92-72(113)58(35-47-37-82-41-86-47)95-68(109)52(25-26-63(104)105)90-69(110)53(27-31-118-4)91-74(115)60(40-100)96-71(112)56(33-45-21-23-48(102)24-22-45)93-73(114)59(39-99)87-43(3)101/h5-9,14-17,21-24,36-37,41-42,51-61,64,84,99-100,102H,10-13,18-20,25-35,38-40,78H2,1-4H3,(H2,79,106)(H,82,86)(H,85,107)(H,87,101)(H,88,103)(H,89,111)(H,90,110)(H,91,115)(H,92,113)(H,93,114)(H,94,108)(H,95,109)(H,96,112)(H,97,116)(H,104,105)(H4,80,81,83)/t51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,64-/m0/s1

SMILES Code: CC(C)[C@@H](C(N)=O)NC([C@H]1N(C([C@H](CCCCN)NC(CNC([C@H](CC2=CNC3=C2C=CC=C3)NC([C@H](CCCNC(N)=N)NC([C@H](CC4=CC=CC=C4)NC([C@H](CC5=CNC=N5)NC([C@H](CCC(O)=O)NC([C@H](CCSC)NC([C@H](CO)NC([C@H](CC6=CC=C(O)C=C6)NC([C@H](CO)NC(C)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CCC1)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 1664.9 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Leung K. Poly(ethylene glycol)-coated gold nanocages bioconjugated with [Nle(4),d-Phe(7)]-α-melanotropin-stimulating hormone. 2011 May 29 [updated 2011 Jul 14]. Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. Available from PubMed PMID: 21755635.

2: Bednarek MA, MacNeil T, Tang R, Fong TM, Cabello MA, Maroto M, Teran A. Potent and selective agonists of alpha-melanotropin (alphaMSH) action at human melanocortin receptor 5; linear analogs of alpha-melanotropin. Peptides. 2007 May;28(5):1020-8. Epub 2007 Feb 17. PubMed PMID: 17376561.

3: Berberian V, Sánchez S, Sánchez-Borzone M, Attademo AM, Lasaga M, Celis ME. Effect of alpha-melanotropin hormone on serum levels of luteinizing hormone and progesterone in experimental rat autoimmune oophoritis. Peptides. 2006 Sep;27(9):2295-9. Epub 2006 May 22. PubMed PMID: 16716456.

4: Pichler R, Sfetsos K, Badics B, Gutenbrunner S, Auböck J. Vitiligo patients present lower plasma levels of alpha-melanotropin immunoreactivities. Neuropeptides. 2006 Jun;40(3):177-83. Epub 2006 May 4. PubMed PMID: 16677711.

5: Pichler R, Crespillo C, Maschek W, Esteva I, Soriguer F, Sfetsos K, Auböck J. Plasma levels of alpha-melanotropin and ACTH-like immunoreactivities do not vary by season or skin type in women from southern and central Europe. Neuropeptides. 2004 Oct;38(5):325-30. PubMed PMID: 15464199.

6: Piatti V, Celis ME, Durando PE. The stimulatory effect of alpha-melanotropin on progesterone release from rat granulosa cells is inhibited by interleukin-1beta and by tumour necrosis factor-alpha. Acta Physiol Scand. 2004 Oct;182(2):145-9. PubMed PMID: 15450110.

7: Muceniece R, Krigere L, Süli-Vargha H, Wikberg JE. Effects of alpha-melanotropin C-terminal tripeptide analogues on macrophage NO production. Peptides. 2003 May;24(5):701-7. PubMed PMID: 12895656.

8: Desai P, Prachand M, Coutinho E, Saran A, Bodi J, Süli-Vargha H. Activity and conformation of a cyclic heptapeptide possessing the message sequence His-Phe-Arg-Trp of alpha-melanotropin. Int J Biol Macromol. 2002 Jun 18;30(3-4):187-95. PubMed PMID: 12063121.

9: Sánchez MS, Barontini M, Armando I, Celis ME. Correlation of increased grooming behavior and motor activity with alterations in nigrostriatal and mesolimbic catecholamines after alpha-melanotropin and neuropeptide glutamine-isoleucine injection in the rat ventral tegmental area. Cell Mol Neurobiol. 2001 Oct;21(5):523-33. PubMed PMID: 11860189.

10: Bednarek MA, MacNeil T, Kalyani RN, Tang R, Van der Ploeg LH, Weinberg DH. Selective, high affinity peptide antagonists of alpha-melanotropin action at human melanocortin receptor 4: their synthesis and biological evaluation in vitro. J Med Chem. 2001 Oct 25;44(22):3665-72. PubMed PMID: 11606131.

11: Bednarek MA, MacNeil T, Tang R, Kalyani RN, Van der Ploeg LH, Weinberg DH. Potent and selective peptide agonists of alpha-melanotropin action at human melanocortin receptor 4: their synthesis and biological evaluation in vitro. Biochem Biophys Res Commun. 2001 Aug 24;286(3):641-5. PubMed PMID: 11511108.

12: Cecilia Cremer M, Silvina Sanchez M, Ester Celis M. Structure-activity studies of alpha-melanotropin fragments on cAMP production in striatal slices. Peptides. 2000 Jun;21(6):803-6. PubMed PMID: 10959000.

13: Bednarek MA, MacNeil T, Kalyani RN, Tang R, Van der Ploeg LH, Weinberg DH. Analogs of lactam derivatives of alpha-melanotropin with basic and acidic residues. Biochem Biophys Res Commun. 2000 May 27;272(1):23-8. PubMed PMID: 10872798.

14: Scimonelli T, Medina F, Wilson C, Celis ME. Interaction of alpha-melanotropin (alpha-MSH) and noradrenaline in the median eminence in the control of female sexual behavior. Peptides. 2000 Feb;21(2):219-23. PubMed PMID: 10764948.

15: Bednarek MA, Silva MV, Arison B, MacNeil T, Kalyani RN, Huang RR, Weinberg DH. Structure-function studies on the cyclic peptide MT-II, lactam derivative of alpha-melanotropin. Peptides. 1999;20(3):401-9. PubMed PMID: 10447101.

16: Bednarek MA, Macneil T, Kalyani RN, Tang R, Van der Ploeg LH, Weinberg DH. Analogs of MTII, lactam derivatives of alpha-melanotropin, modified at the N-terminus, and their selectivity at human melanocortin receptors 3, 4, and 5. Biochem Biophys Res Commun. 1999 Jul 22;261(1):209-13. PubMed PMID: 10405347.

17: Lezcano NE, Salvatierra NA, Celis ME. Alpha-melanotropin hormone inhibits the binding of [3H]SCH 23390 to the dopamine D1 receptor in vitro. Eur J Pharmacol. 1998 Dec 18;363(2-3):211-5. PubMed PMID: 9881592.

18: Giblin MF, Wang N, Hoffman TJ, Jurisson SS, Quinn TP. Design and characterization of alpha-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination. Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):12814-8. PubMed PMID: 9788997; PubMed Central PMCID: PMC23606.

19: Loir B, Sales F, Deraemaecker R, Morandini R, Garcia-Borron JC, Ghanem G. alpha-Melanotropin immunoreactivity in human melanoma exudate is related to necrosis. Eur J Cancer. 1998 Feb;34(3):424-6. PubMed PMID: 9640235.

20: Prachand MS, Dhingra MM, Saran A, Coutinho E, Bodi J, Süli-Vargha H, Medzihardszky K. Comparative conformational studies on cyclic hexapeptides corresponding to message sequence His-Phe-Arg-Trp of alpha-melanotropin by NMR. J Pept Res. 1998 Apr;51(4):251-65. PubMed PMID: 9560000.

Additional Information